Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …

The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …

The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …

Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with
increased surveillance and improved systemic control, the incidence is likely to grow …

Purpose Cancer spread to the central nervous system (CNS) often is diagnosed late and is
unresponsive to therapy. Mechanisms of tumor dissemination and evolution within the CNS …

Introduction Metastatic spread to the brain is common in patients with non–small cell lung
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials …

Introduction: Many patients with oncogene-driven non–small-cell lung cancer (NSCLC)
treated with tyrosine kinase inhibitors experience limited sites of disease progression. This …